SCHEMBL31145938

SCHEMBL31145938

COC(=O)C(C)c1c(C)c2cnccc2[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 5/20 0.44
▸ PARP1 P09874 4/20 0.44
▸ CSNK2A1 P68400 2/20 0.44
▸ KDM5B Q9UGL1 1/20 0.44
▸ ACHE P22303 3/20 0.41
▸ FEN1 P39748 1/20 0.39
▸ ROCK2 O75116 1/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ DAO P14920 1/20 0.37
▸ APOBEC3G Q9HC16 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31145968 0.85 PARP1 (0.47) KDM5APARP1CSNK2A1KDM5BACHE
SCHEMBL31146055 0.77 PDE3B (0.38) KDM5AKDM5BKMT2AMEN1ALDH1A1
SCHEMBL31145950 0.76 BRD4 (0.36) KDM5AKDM5BKMT2AMEN1ALDH1A1
SCHEMBL31146126 0.74 KDM4E (0.45) KDM5APARP1CSNK2A1KDM5BKMT2A
SCHEMBL31146205 0.73 ACHE (0.41) KDM5APARP1CSNK2A1ACHEROCK2
SCHEMBL25432233 0.72 PARP1 (0.54) KDM5APARP1CSNK2A1KDM5BACHE
SCHEMBL31139875 0.72 PARP1 (0.54) KDM5APARP1CSNK2A1KDM5BACHE
SCHEMBL7123033 0.72 PARP1 (0.50) KDM5APARP1KDM5BACHEFEN1
SCHEMBL31146052 0.70 PARP1 (0.42) KDM5APARP1CSNK2A1ACHEFEN1
SCHEMBL31145905 0.69 PIM1 (0.47) KDM5APARP1CSNK2A1KDM5BACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A KDM5A 3091/4885PARP1 2033/4885CSNK2A1 207/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A KDM5A 3091/4885PARP1 2033/4885CSNK2A1 207/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 KDM5A 3803/4885PARP1 3281/4885CSNK2A1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback